Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 14/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.78 |
| ▸ | CNR1 | P21554 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | BRAF | P15056 | 1/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4256144 | 0.89 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL4259533 | 0.89 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL4265638 | 0.88 | EPHX2 (1.00) | EPHX2HRH3 | |
| SCHEMBL4266421 | 0.85 | EPHX2 (1.00) | EPHX2BRAFMAPK14 | |
| SCHEMBL4262609 | 0.85 | EPHX2 (1.00) | EPHX2HRH3BRAFMAPK14 | |
| SCHEMBL31372656 | 0.85 | EPHX2 (0.72) | EPHX2HRH3 | |
| SCHEMBL23747761 | 0.85 | EPHX2 (0.73) | EPHX2HRH3CNR1SMN1; SMN2BRAF | |
| SCHEMBL4259984 | 0.85 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL4269280 | 0.83 | EPHX2 (0.86) | EPHX2 | |
| SCHEMBL30417063 | 0.81 | SMN1; SMN2 (0.85) | EPHX2CNR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023731-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-01-22 | — | — | US | claimed |
| US-20090023731-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090023731-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090023731-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-01-22 | — | — | US | disclosed |
| WO-2008116145-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008116145-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023731-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885HRH3 163/4885CNR1 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.